Oncor news

OncorPharm will conduct the preclinical testing of products and then will license or establish joint ventures to further their development. "My business is selling IND packages to pharmaceutical companies," said William Ryan, president and CEO of the subsidiary.

The company hopes to file an IND within 12-24 months on a technology to treat basal cell cancer with point mutations in the p53 gene. A second product will target a single point mutation in the hemoglobin B gene to treat sickle cell anemia. ...